C ardiac hypertrophy is an essential adaptive or maladaptive response of myocytes to diverse pathophysiological stimuli (eg, hypertension, ischemia, valvular insufficiency and stenosis, or sarcomeric gene mutations).
been investigated. Therefore, determining whether a deficiency in or the overexpression of IRF9 in the myocardium could affect the process of heart disease is important.
In the present study, we first identified IRF9 as an endogenous negative regulator of cardiac hypertrophy and observed that IRF9 was significantly activated in an aortic banding (AB)-induced animal model of cardiac hypertrophy. Compared with the controls, the IRF9-deficient mice developed more severe hypertrophy upon stimulation, whereas IRF9 overexpression in the heart suppressed this pathological process. In addition, we provided evidence that myocardin is an important target of IRF9 because its transcriptional activity is strongly suppressed in the presence of IRF9.
Materials and Methods
All animal experimental protocols were approved by the Animal Care and Use Committee of Renmin Hospital of Wuhan University. An expanded Methods section is available in the online-only Data Supplement, including Reagents, Animal Models and Procedures, 3, [14] [15] [16] [17] Echocardiography and Hemodynamic Measurements, 14, 18, 19 Histological Analysis, Cultured NRCMs and Recombinant Adenoviral Vectors, 14, 16 Immunofluorescence Analysis, Western Blotting, and Quantitative Real-Time PCR, Plasmid Constructs, 13 Immunoprecipitation and the GST Pull-down Assay, Luciferase Reporter Assays, 20 EMSA, 17, 21, 22 and Statistical Analysis.
Results

IRF9 Levels Are Elevated During Cardiac Hypertrophy
To investigate the role of IRF9 in the development of cardiac hypertrophy and heart failure, we first measured IRF9 expression in murine hypertrophic hearts and neonatal rat cardiomyocytes (NRCMs). Both Western blot analysis and reverse transcription polymerase chain reaction demonstrated that IRF9 levels were significantly upregulated in the hearts of mice that underwent AB for 2 or 4 weeks ( Figure 1A ; Figure S1 in the online-only Data Supplement). As shown in Figure 1A , compared with the sham-operated control hearts, IRF9 protein levels were ≈3-fold and 5-fold higher in the experimental mouse hearts after 2 or 4 weeks of AB, respectively; this increase was also observed at the mRNA level ( Figure S1 ). In addition, the increase in IRF9 correlated with an increase in the hypertrophy markers β-myosin heavy chain (β-MHC) and atrial natriuretic peptide (ANP) ( Figure 1A) . Furthermore, the stimulation of NRCMs with isoproterenol (ISO; 10 μmol/L) or angiotensin II (Ang II; 1 μmol/L) for 48 hours to induce hypertrophy resulted in the upregulation of IRF9, β-MHC, and ANP ( Figure 1B ). These results indicate that IRF9 is markedly activated by hypertrophic stress in vivo and in vitro, which suggests that IRF9 may be involved in cardiac hypertrophy.
IRF9-Deficient Mice Exhibit an Increased Susceptibility to Pathological Cardiac Hypertrophy
We then examined the potential function of IRF9 during hypertrophy in vivo, subjecting global homozygous IRF9 gene knockout (IRF9 −/− ) mice to 4 weeks of AB; these mice did not produce IRF9 protein in the heart ( Figure S2A ) and did not display apparent phenotypic abnormalities at baseline (Table S1 ). After 4 weeks of AB, we observed a higher mortality rate in the IRF9 −/− mice than in the wild-type littermates (IRF9 +/+ ; Figure S2B ). The IRF9 −/− mice also exhibited enhanced hypertrophy compared with the IRF9 +/+ mice for 4 weeks of AB, as indicated by the higher ratios of heart weight to body weight (HW/BW), lung weight to BW, and HW to tibia length in the knockout mice ( Figure 2A ). No comparable differences were noticed in the sham-operated IRF9 −/− and IRF9 +/+ mice ( Figure 2A ). Hematoxylin-eosin and wheat germ agglutinin staining showed a greater ventricular cross-sectional area in the IRF9 −/− mice than in the controls ( Figure 2B and 2C), further confirming that IRF9 deficiency promoted the development of AB-induced cardiac hypertrophy. We also performed echocardiography and hemodynamic measurements to monitor the cardiac function of the IRF9 −/− and IRF9 +/+ mice after hypertrophic stimuli. After 4 weeks of AB, the IRF9 −/− mice exhibited reduced cardiac function (Table S2 ). In response to AB, the expression levels of ANP, B-type natriuretic peptide, and β-MHC were dramatically higher in the IRF9 −/− mice than in the controls ( Figure S2C ; Figure 2D ). Histological analysis with picrosirius red staining revealed more extensive perivascular and interstitial fibrosis in the hearts of IRF9 −/− mice at 4 weeks after AB ( Figure 2E and 2F). Subsequently, these results were corroborated by detecting the mRNA levels of fibrotic markers such as connective tissue growth factor, collagen I, and collagen III ( Figure S2D ). Thus, IRF9 is an endogenous negative regulator of cardiac hypertrophy.
IRF9 Overexpression Suppresses AB-Induced Cardiac Hypertrophy
To further confirm the inhibitory effect of IRF9 on cardiac hypertrophy, cardiac-specific transgenic (TG) mice that overexpress murine IRF9 under the control of the α-MHC promoter were generated ( Figure S3A ), and 4 independent lines of IRF9-TG mice were established. Western blot analysis indicated that cardiac IRF9 expression in these TG mice was 2-to 6-fold higher than that in their non-TG (NTG) littermates ( Figure S3B ). However, at baseline, the IRF9-TG mice developed normally, with no apparent structural or functional deficits (Table S1 ). The 4 IRF9-TG mouse lines exhibited a similar phenotype after 4 weeks of AB (data not shown), and TG line No. 9 mice and their littermates were used for further experiments. As shown in Figure 3A , AB induced a 51% increase in the HW/BW ratio, indicating the development of cardiac hypertrophy in the NTG mice, whereas the TG mice exhibited significantly blunted hypertrophic growth, with an increase of ≈18% in the HW/BW ratio ( Figure 3A) . Similar effects were also observed in the lung weight/BW and HW/tibia length ratios ( Figure 3A ). Histological analysis revealed that the IRF9-TG mice exhibited markedly smaller AB-induced increases in ventricular cross-sectional area and cardiac fibrosis than did the NTG mice ( Figure 3B , 3C, 3E, and 3F; Figure S3D ). These changes are consistent with the protective role of IRF9 in cardiac function in response to hypertrophic stimulation, as measured by echocardiography (Table S3) . Furthermore, AB increased the expression of ANP, B-type natriuretic peptide, and β-MHC in the hearts of the NTG mice, and this expression was significantly suppressed in the IRF9-TG mice ( Figure 3D ; Figure S3E ). In addition, no comparable differences in death rate were observed between the NTG and IRF9-TG mice ( Figure S3C ). Together, these 
IRF9 Inhibits ISO-Induced Cardiac Hypertrophy
The above findings clearly demonstrate that IRF9 protects the heart from AB-induced cardiac hypertrophy, but different hypertrophic stimuli have been reported to act on different receptors and induce different molecular responses. 23, 24 Therefore, we used another classic method for inducing hypertrophy, ISO infusion, to determine whether IRF9 is a general regulator of the development of cardiac hypertrophy. Consistent with the results observed during AB, after ISO infusion (30 mg/kg per day) for 4 weeks, the ratios of HW/BW, lung weight/BW, and HW/tibia length were dramatically higher in the IRF9 −/− mice than in the IRF9 +/+ mice ( Figure S4A ), whereas these ratios were markedly lower in the TG mice than in the NTG mice ( Figure S4G ). In addition, compared with the controls, the IRF9 −/− mice exhibited more severe hypertrophic responses to ISO as indicated by a greater ventricular cross-sectional area and increased cardiac fibrosis ( Figure S4B-S4D) , whereas the hearts of the IRF9-TG mice were smaller and exhibited less cardiac fibrosis in response to ISO than the control mice ( Figure  S4H-S4J) . Echocardiography of the IRF9 −/− mice revealed significantly reduced cardiac function on ISO infusion; however, the IRF9-TG mice exhibited mild ventricular dilatation and cardiac dysfunction (Table S4) . Furthermore, ISO induced the expression of fetal genes, and fibrotic markers were elevated in the hearts of the IRF9 −/− mice but significantly reduced in the hearts of the TG mice ( Figure S4E , S4F, S4K, and S4L). Similar results from ISO infusion further confirmed that IRF9 is generally required to protect the heart from pathological hypertrophy.
IRF9 Inhibits the Ang II-Induced Hypertrophic Response in Cardiomyocytes
We next tested whether IRF9 contributes to the hypertrophy of cardiomyocytes in vitro. NRCMs were infected with AdshIRF9, AdIRF9, or control vectors ( Figure 4A ) and Immunostaining with the α-actinin antibody indicated that AdshIRF9 treatment enhanced Ang II-induced increase in cell size, whereas overexpression of IRF9 (AdIRF9), but not the control vector, suppressed the hypertrophic response to Ang II stimulation ( Figure 4B and 4C). Furthermore, the ANP and β-MHC mRNA levels were significantly higher in the NRCMs infected with AdshIRF9 after exposure to Ang II than in controls ( Figure 4D ). However, IRF9 overexpression attenuated the elevation of ANP and β-MHC levels induced by Ang II ( Figure 4E ). Taken together, these observations indicate that IRF9 suppresses the hypertrophic response in cardiomyocytes.
IRF9 Interacts With Myocardin and Represses Its Transcriptional Activity
Once we found that IRF9 is capable of inhibiting pathological hypertrophy, we investigated the mechanism by which this effect occurs. A dual-luciferase reporter analysis was performed to identify the IRF9-regulated target using a Cignal 45-Pathway Reporter Array kit. We found that the activity of the luciferase reporter linked to the CArG box (which serves as the SRF-binding site) was dramatically inhibited by IRF9, and this result was further confirmed in NRCMs ( Figure S5A ). Our results showed that IRF9 overexpression significantly suppressed Ang II activation of a luciferase reporter linked to 3 tandem copies of a CArG box ( Figure S5A ). The CArG box is found in the ANP promoter and regulates its promoter activity 20, 25 ; thus, we also examined the effect of IRF9 on ANP activity. Consistent with the CArG box results, IRF9 overexpression also suppressed the luciferase activity of ANP induced by Ang II in NRCMs ( Figure S5A ). To determine whether the inhibitory effect of IRF9 on the expression of CArG box-dependent reporters resulted from influencing SRF expression, we tested the activity of a luciferase reporter linked to the promoter of SRF. The results showed that IRF9 overexpression did not alter the Ang II-induced luciferase activity controlled by the SRF promoter in the NRCMs ( Figure S5B ). Furthermore, a coimmunoprecipitation assay performed in HEK293T cells showed that IRF9 did not directly interact with SRF (data not shown). On the basis of the above findings, we next determined the effect of IRF9 on the activity of myocardin, a well-characterized coactivator of SRF that potently transactivates the CArG box. 26, 27 As shown in Figure S5C , IRF9 overexpression strongly suppressed the ability of myocardin to activate the CArG boxdependent reporters ( Figure S5C ). In addition, the IRF9 −/− mice exhibited enhanced myocardin transcriptional activity compared with the IRF9 +/+ mice for 4 weeks of AB ( Figure  S5D ). This effect was specific to myocardin and independent of SRF as demonstrated by the fact that the activation of the GAL4-dependent reporter by myocardin that is linked to the GAL4 DNA-binding domain was also markedly suppressed by IRF9 ( Figure S5E ). To define the mechanism responsible for the IRF9 suppression of myocardin activity, we performed a glutathione S-transferase (GST) pull-down assay to determine whether IRF9 interacts directly with myocardin. As shown in Figure 5A , IRF9 did bind to myocardin. This interaction was further confirmed with a coimmunoprecipitation assay ( Figure 5B ). Subsequently, we mapped the domains of IRF9 and myocardin that are responsible for this interaction. Both the N terminus (residues 1-120) and the proline-rich (pro) domain (residues 120-220) of IRF9 contributed to myocardin binding ( Figure 5C ). However, the transcription activation domain (TAD; residues 738-938) of myocardin specifically interacted with IRF9 ( Figure 5D ). To determine whether the inhibitory effect of IRF9 on myocardin activity depends on this direct interaction, we tested the effect of an IRF9 mutant that lacks the myocardin-binding domain and found that this IRF9 mutant did not affect the activation of the CArG box-dependent reporters by myocardin ( Figure S5F) .
The IRF9 association domain of myocardin, the TAD, is also bound by p300. p300 enhances myocardin activity in African green monkey simian virus 40 transformed kidney cell (COS cells) by interacting directly with the TAD of myocardin, 25 and this effect was also observed in NRCMs and H9C2 cells ( Figure S5G and S5H ). IRF9 and p300 bind to the same region of myocardin and have opposite effects on myocardin activity; thus, we cotransfected H9C2 cells with different doses of IRF9 and p300 to determine the relationship between these 2 regulators. As shown in Figure S5I , IRF9 competed with p300 to modulate the transcriptional activity of myocardin in H9C2 cells. Furthermore, IRF9 significantly inhibited the p300-mediated activity of myocardin in the NRCMs ( Figure  S5G ). To determine whether the binding activity of myocardin is truly required for IRF9 function, we tested the luciferase activities of 2 mutated ANP promoters lacking 1 or 2 CArG box sequences, as previously reported. 20 As shown in Figure S5J , myocardin activated the luciferase reporter that was linked to the wild-type ANP promoter (ANP-1000), and this effect was further enhanced after knocking down IRF9. Furthermore, deletion of the distal CArG box from the ANP promoter (ANP-236) led to a small increase in the transcriptional activity of myocardin after interfering IRF9 expression, and IRF9 was not able to alter the luciferase activity of ANP-121, which lacks both CArG boxes in the ANP promoters ( Figure S5J) . Therefore, the role of IRF9 depends on myocardin binding to the target gene promoter. Taken together, these data indicate that IRF9 interacts directly with myocardin and thereby suppresses its transcriptional activity.
Discussion
The results of this study are compelling evidence of the critical role of IRF9 in pathological cardiac hypertrophy. We observed that the level of IRF9 was elevated by hypertrophic stimuli. Subsequently, we showed that IRF9 protected against pressure overload-induced cardiac hypertrophy: IRF9 −/− mice exhibited an augmented hypertrophic response after 4 weeks of AB or ISO infusion, whereas hypertrophic growth was reduced in the cardiac-specific IRF9 TG mice. Furthermore, we identified that IRF9 exerted an antihypertrophic effect by binding to the TAD of myocardin, thus suppressing its transcriptional activity. Notably, this interaction also inhibited p300-mediated activation of myocardin.
Members of the IRF family participate in the regulation of many biological processes, including the innate and adaptive immune responses, antiviral defense, cell growth and apoptosis, oncogenesis, and hematopoietic development. [28] [29] [30] However, little is known about the functions of IRFs in the cardiac system. Recently, we have demonstrated that IRF3 and IRF4 are involved in regulating cardiac hypertrophy.
14,15 IRF3 acts as a negative regulator of cardiac hypertrophy by blocking the extracellular regulated protein kinases 1/2 (ERK1/2) signaling pathway, 15 and IRF4 aggravates pathological cardiac hypertrophy by activating the cAMP response elementbinding protein.
14 It is not surprising that both IRF3 and IRF4 function in cardiac hypertrophy because different IRFs have many features in common. 31 For example, most IRFs regulate cell growth. The specific function of each member of the IRF family must be investigated because both common and specific features enable members of the IRF family to receive, integrate, and transmit signals arising from a diverse array of stresses. Like IRF3 and IRF4, IRF9 is expressed in the heart; however, IRF9 exhibits a different expression pattern than either IRF3 or IRF4 in response to hypertrophic stress. IRF3 expression increased to maximal levels in the hearts of mice subjected to AB at day 14 and then decreased to basal levels at day 28, 15 whereas IRF4 was downregulated during cardiac hypertrophy.
14 In contrast, the IRF9 level was markedly elevated in pathological hypertrophic hearts. This phenomenon suggests that IRF9 may play a specific role in cardiac hypertrophy that is different from the roles of IRF3 and IRF4.
The mechanism by which hypertrophic stress elevates the IRF9 levels has not yet been studied. Nevertheless, a mechanism can be hypothesized based on the studies of other negative regulators of cardiac hypertrophy. One feature of hypertrophy is enhanced protein synthesis, including that of numerous positive and negative factors. Several endogenous molecules such as inducible cAMP early repressor (ICER), myocyte-enriched calcineurin-interacting protein 1 (MCIP1), and suppressor of cytokine signaling-3 (SOCS3) have been relatively well characterized and exhibit increased expression on hypertrophic stimulation. [32] [33] [34] [35] The results of these studies are similar to our observations of IRF9, and this increased expression may be a compensatory cardiac response to the detrimental effects of hypertrophy. Another mechanism may contribute to the increased IRF9 level because a negativefeedback pathway related to IRF9 may exist. Consistent with our results, the expression of IRF9 in cardiomyocytes at baseline is low, 36 and the increased level of IRF9 induced by hypertrophic stress may in turn inhibit upstream pathways. Further studies are needed to understand the mechanisms by which IRF9 expression is regulated during stress.
After hypertrophic stimulation, IRF9 overexpression strongly inhibits the expression of a luciferase reporter linked to the CArG box, which is the binding site of SRF and is required for SRF-target gene expression 27 ; however, SRF is not the direct target of IRF9 because the luciferase activity controlled by SRF promoter did not change after IRF9 overexpression, and no interaction between IRF9 and SRF was detected. As a transcription factor, SRF is a relatively weak transcriptional activator and must recruit cofactors for transcriptional activity. 37 Thus, we further investigated the effect of IRF9 on the cofactors of SRF. Subsequently, myocardin was identified as the target of IRF9. As an important coactivator of SRF, myocardin participates in cardiac and smooth muscle differentiation and mediates cardiac development and hypertrophy. 27, 38, 39 The mapping experiment determined that both the N terminus and the pro-domain of IRF9 are responsible for the interaction with myocardin. The N terminus of IRF9 is the DNA-binding domain, which is characterized by 5 tryptophan repeats and is highly conserved within the IRF family. 30 The pro-domain corresponds to a linker region, 13, 40 which is reported to be the PPARα-binding domain. 13 Only the TAD of myocardin contributes to the association with IRF9. The TAD of myocardin, as its name indicates, possesses powerful transcriptional activity and acts through CArG boxes in genes. 27 Furthermore, when the TAD is absent, myocardin fails to induce hypertrophy in cardiomyocytes. 39 The binding of IRF9 to the TAD of myocardin results in a marked inhibition of its transcriptional activity, thereby influencing the development of cardiac hypertrophy.
Intriguingly, p300 also interacts directly with the TAD of myocardin, but this interaction activates myocardin. 25 IRF9 and p300 bind to the same region of myocardin, and we subsequently discovered that IRF9 competes with p300 to modulate the activity of myocardin. In other words, the opposing effects of IRF9 and p300 on myocardin activity seem to the result of direct competition for the same site on myocardin. The repressive influence of IRF9 seems to be dominant because p300 overexpression was unable to completely abrogate the inhibitory effect of IRF9 on the transcriptional activity of myocardin in H9C2 cells, and IRF9 overexpression significantly suppressed the effect of p300 on myocardin activity in NRCMs. Although our results might not exclude other mechanisms by which IRF9 suppresses cardiac hypertrophy, the inhibitory effect of IRF9 on the development of cardiac hypertrophy seems to be largely dependent on the repression of myocardin activity by IRF9. In summary, we demonstrated that IRF9 suppresses the development of cardiac hypertrophy both in vitro and in vivo. Furthermore, we identified myocardin as a new target of IRF9 and demonstrated that the transcriptional activity of myocardin is strongly inhibited by IRF9. Thus, targeting IRF9 might be a useful therapeutic strategy to prevent cardiac hypertrophy and heart failure. 
Animal Models and Procedures
All the animal experimental protocols were approved by the Animal Care and Use Committee of Renmin Hospital Wuhan University. A full-length mouse IRF9 cDNA was ligated into the α-MHC promoter expression vector. This DNA construct was microinjected into fertilized mouse embryos (C57BL/6J background),and the resulting transgenic mice (IRF9-TG) were PCR-genotyped using the tail genomic DNA and the following primers: forward:5'-ATCTCCCCCATAAGAGTTTGAGTC-3' and reverse: 5'-GTTGAGGGCACAGCGTAG-3'. Global IRF9 knockout mice (IRF9-/-, C57BL/6J background) were obtained from Dr. Taniguchi Tadatsugu (The University of Tokyo). The IRF9-/-and the IRF9-TG mice as well as their wild-type littermates (C57BL/6J background) were analyzed at 8 to 10 weeks.
A pressure overload was produced by aortic banding (AB) as previously described [1] [2] [3] [4] [5] . Briefly, thoracic aortas were located following dissection at the second intercostal space after mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.; Sigma, St. Louis, MO, USA) and did not display any foot reflex. The thoracic aortas were banded against a 27G (for body weights of 24-25 g) or 26G (for body weights of 26-27 g) needle that was removed before closing the thoracic cavity with a 7-0 silk suture. In addition, Doppler analysis was used to verify adequate constriction of the aortas. A sham-operated group underwent a similar procedure without aortic constriction. For ISO infusion, ISO was dissolved in 50 mM ascorbic acid and administered for 4 weeks (30 mg/kg/day) by subcutaneously implanting Alzet osmotic minipumps (Alzet model 2004).
Echocardiography and Hemodynamic Measurements
After the indicated time, the surviving mice were anesthetized with 1.5-2% isoflurane and subjected to echocardiography and hemodynamic measurements to examine cardiac function and structure as previously described 2, 6, 7 . To measure the left ventricle (LV) end-systolic dimension (LVESD), LV end-diastolic dimension (LVEDD) and LVFS [LVFS (%) = (LVEDD-LVESD/LVEDD) × 100%], we 2 performed echocardiography with a Mylab30CV (ESAOTE) machine equipped with a 15-MHz probe. M-mode tracings were recorded from the short axis of the left ventricle, and the LV internal diameter was measured based on at least three beats. The hemodynamic parameters were determined using a 1.4-French Millar catheter-tip micromanometer catheter (SPR-839; Millar Instruments) inserted through the right carotid artery into the left ventricle. An Aria pressure-volume conductance system coupled with a Powerlab/4SP A/D converter was used to continuously record and store the pressure and dp/dt, which were then displayed on a personal computer.
Histological Analysis
The animals were sacrificed 4 weeks after AB or sham surgery. The hearts were arrested with a 10% potassium chloride solution at end-diastole and then fixed in 10% formalin. Paraffin-embedded hearts were cut transversely into 4-5 -µm sections. Heart sections were stained with HE and PSR (to detect collagen). Cross-sectional areas of the myocytes were visualized with FITC-conjugated WGA (Invitrogen) staining, and the cell size was measured using a quantitative digital image analysis system (Image-Pro Plus 6.0).
Cultured NRCMs and Recombinant Adenoviral Vectors
Primary cultures of NRCMs from 1-to 2-day-old Sprague-Dawley rats were prepared as described previously 2, 4 . Briefly, the ventricles were enzymatically dissociated into individual cardiomyocytes in PBS containing 0.03% trypsin and 0.04% type II collagenase. After removing the fibroblasts using a differential attachment method, NRCMs were plated at a density of 1×10 6 cells/well onto gelatin-coated culture dishes in cardiomyocyte culture medium (DMEM/F12 medium supplemented with 20% fetal calf serum, 0.1 mM BrdU and penicillin/streptomycin). To induce hypertrophy, cardiomyocytes were maintained in serum-free DMEM/F12 for 12 hours and treated with ISO (10 μM) and Ang II (1 μM). AdIRF9, a recombinant adenovirus that expresses rat IRF9, was generated by subcloning full-length rat IRF9 cDNA under the control of the cytomegalovirus (CMV) promoter into a replication-defective adenoviral vector. AdIRF9 was modified to express green fluorescent protein (GFP). Three rat shIRF9 constructs were obtained from SABiosciences (KR48866G). Subsequently, AdshIRF9 adenoviruses were generated, and the construct that led to the most significant decrease in IRF9 levels was selected for further experiments. AdshRNA was used as the control. NRCMs were infected with recombinant adenoviruses at a multiplicity of infection (MOI) of 25 particles per cell for 24 hours.
Immunofluorescence Analysis
Immunofluorescence analysis was performed using standard immunocytochemical techniques. Briefly, NRCMs cultured on gelatin-coated cover slips were infected with the indicated recombinant adenoviruses for 24 hours and then treated with hypertrophic stimuli for 48 hours. Subsequently, the cardiomyocytes were fixed with 3.7% formaldehyde for 15 minutes, permeabilized with 0.1% Triton X-100 in PBS for 40 minutes, blocked with a 10% BSA solution for 1 hour at room temperature and 3 then incubated with an anti-α-actinin antibody (1:100 dilution). The surface areas were measured using Image-Pro Plus 6.0 software.
Western Blotting and Quantitative Real-Time PCR
Whole-cell lysates were obtained by homogenizing the hearts or NRCMs in RIPA lysis buffer. The proteins (50 μg) were resolved via SDS-PAGE (Invitrogen) and transferred to a PVDF membrane (Millipore). The membrane was blocked with 10% non-fat milk and then incubated with the indicated primary antibodies overnight at 4°C. The membrane was then incubated with a secondary IRDye® 800CW-conjugated antibody (Li-Cor Biosciences), and an Odyssey Imaging System (Li-Cor Biosciences) was used for signal detection. Total RNA was isolated from heart tissues or NRCMs using TRIzol Reagent (Invitrogen), and the Transcriptor First Strand cDNA Synthesis Kit (Roche) was used to synthesize cDNA. The mRNA levels of the indicated genes were quantified with real-time PCR using SYBR Green (Roche). The real-time PCR primers that were used are shown in Table S4 .
Plasmid Constructs EGFP-myc-IRF9, GST-IRF9 and IRF9 fragments consisting of residues 1 to 120, 210 to 393 and 120 to 220 were generated as previously reported 8 . Flag-myocardin and pCherry-myocardin constructs were generated by amplifying the coding region of the myocardin gene with the primers MyoD-5' and MyoD-3' from human cDNAs and cloning the gene into psi-Flag-C1 and psi-Cherry-C1. To obtain the myocardin fragments comprising residues 1 to 738 and 738 to 938, Flag-myocardin was amplified via PCR with MyoD-5' and MyoD-N-3' or MyoD-C-5' and MyoD-3', respectively. The products were digested with XhoI and ligated into psi-Flag to create an in-frame fusion with the Flag tag. The primers used to generate these constructs are provided in Table S3 . All plasmids were verified by sequencing.
Immunoprecipitation and the GST Pull-down Assay EGFP-myc-IRF9 and Flag-myocardin were co-transfected into 293T cells for 48 hours. The cells were lysed at 4°C in immunoprecipitation (IP) buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA and 0.5% NP-40) supplemented with protease inhibitor cocktail (Roche), and then sonicated. The resulting lysates were incubated for 20 minutes at 4°C and then centrifuged at 13,000×g for 15 minutes at 4°C. For each IP, 500 μl of the supernatant was incubated with 1 μg of the indicated antibodies and 10 μl of Protein A/G-agarose beads (11719394001, 11719386001, Roche) on a rocking platform overnight at 4°C. The beads were washed 5-6 times with cold IP buffer, and the proteins were subsequently analyzed by Western blotting.
The GST-IRF9 plasmid was transformed into Rosetta (DE3) E. coli. After induction with isopropyl-β-D-thiogalactopyranoside (IPTG) for 4-6 hours, 10 ml of the culture was harvested, and the GST fusion protein was purified using glutathione-sepharose 4B beads (GE Healthcare Bio-Sciences AB). Immobilized GST-IRF9 fusion proteins were incubated with Flag-Myocardin -transfected 293T cell 4 lysates in IP buffer for 4 hours at 4 °C. The beads were washed four times with IP buffer before the loading buffer was added and then analyzed by Western blotting. The GST tag was used as a negative control under the same conditions.
Luciferase Reporter Assays
The SRF-luc plasmid was obtained by cloning approximately 1,500 bp of the SRF promoter (-1354~+184) into the pGL3-basic vector (Promega). The CArG-luc plasmid was produced by inserting three CArG consensus sequences into the pGL3-promoter vector (Promega).The ANP-luc plasmid was constructed as previously reported 9 . The primers used to make this construct are listed in Table S3 . NRCMs and H9C2 cells were cultured in 24-well plates. NRCMs were infected with the indicated recombinant adenoviruses, and the plasmids encoding myocardin, p300 and IRF9 together with 3xCArG-luc or ANP-luc were co-transfected into H9C2 cells. The cells were harvested 48 hours later and lysed with 100 µl of passive lysis buffer (PLB, Promega). After removing cell debris by centrifugation, the supernatant was used for luciferase assays performed using a Single-Mode SpectraMax® Microplate Reader according to the manufacturer's instructions. Luciferase activities were normalized based on protein content.
A Cignal 45-Pathway Reporter Array (SABiosciences, CCA-901L) was used to simultaneously test 45 different pathways in H9C2 cells according to the manufacturer's protocol. Briefly, 200ng of GFP or IRF9 plasmid diluted in 50μl Opti-MEM® was added to each well of the Cignal Finder Array plate, and then resuspend the reporter assay constructs resident in the well. After incubating at room temperature for 5 minutes, 0.6 μl of Attractene Transfection Reagent (QIAGEN) diluted in 50 μl of Opti-MEM® was added to each well. Cells were suspended in Opti-MEM® containing 10% of fetal bovine serum and then 50 µl of the cell suspension was added into each well and mixed with the constructs-Attractene complexes. After 16 hours of transfection, the medium was replaced by complete growth medium (DMEM with 10% FBS, 0.1mM NEAA, 1mM Sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin). After transfection for 48 hours, the luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega).
Electrophoretic mobility shift assays (EMSA)
The EMSA assay was performed as our previously described 5, 10, 11 . Sequence of the DNA oligonucleotide was 5'-CCGAACTGATAACTTTAAAAGGGCATCTTCTG C-3'. 1μL 32 P-labled oligonucleotide probe was incubated with10μg nuclear protein of mouse hearts for 30 min at room temperature in binding buffer (20 mM Hepes, 25 mM KCl, 10% glycerol, 2 mM MgCl2 and 10 mM DTT).Reaction was stopped by adding 1μL of loading buffer and the mixture was subjected to 5% polyacrylamide gel electrophoresis in 0.5 × TBE buffer. After electrophoresis (390V, 1hour), the gel was autoradiographed. 5 The data are presented as the mean ± SD. Statistical analysis was performed using SPSS 13.0 software to conduct an unpaired 2-tailed Student's t test (for two groups) and a one-way or two-way ANOVA test followed by the Bonferroni post hoc test (for more than two groups). P values of less than 0.05 were considered statistically significant.
Statistical analysis
Table S5
The primers for vector construct.
Primer name
Primer sequence (5′-3′)
MyoD-5' CCGCTCGAGATGACACTCCTGGGGTCTGAG
MyoD-3' CCGCTCGAGCTACCACTGCTGCAAGTGAAG
MyoD-N-3' CCGCTCGAGCTAATCCATCTGCTGACTCCGGGT
MyoD-C-5' CCGCTCGAGCAGCAGATGGATGAACTCCTG
SRF-promoter-5' GCCAGATCTTGTCACTTGTTTCCAGGCA
SRF-promoter-3' GCCAAGCTTCTAGTGCCGCTATCGCTG
The underlined sequences are the sites for restriction enzyme 
